CO6150178A2 - Derivados de pirazol como inhibidores de la citocromooxidasa p450 - Google Patents

Derivados de pirazol como inhibidores de la citocromooxidasa p450

Info

Publication number
CO6150178A2
CO6150178A2 CO09010549A CO09010549A CO6150178A2 CO 6150178 A2 CO6150178 A2 CO 6150178A2 CO 09010549 A CO09010549 A CO 09010549A CO 09010549 A CO09010549 A CO 09010549A CO 6150178 A2 CO6150178 A2 CO 6150178A2
Authority
CO
Colombia
Prior art keywords
cr9r10
cycloalkyl
alkyl
groups
independently selected
Prior art date
Application number
CO09010549A
Other languages
English (en)
Inventor
Simon Paul Planken
Scott Channing Sutton
Rongliang Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO6150178A2 publication Critical patent/CO6150178A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Un compuesto de fórmula (I)en la que, R1 es alquilo C1-C8, -(CR9R10)R11, -(CR9R10)tC(O)R11, -(CR9R10)tC(O)N(R13R14), -(CR9R10)t-(heterociclil de 3-10 miembros)-R11 o -(CR9R10)(heteroaril de 5-9 miembros)-R11; R2 es heteroarilo de 5-9 miembros, opcionalmente sustituido con uno o más grupos R11;R3, R4, R5, R6, R7 y R8 se selecciona cada uno de forma independiente de hidrógeno, halógeno, alquilo C1-C8, alquenilo C2-C8, alquinilo C2-C8, -(CR9R10)t(cicloalquiIo C3-C8), -(CR9R10)tOR11, -(CR8R10)tN(R11R12), -CN, -NO2, -CF3, -C(O)R9 y -C(O)2R9;cada R9 y R10 se selecciona de forma independiente de hidrógeno, alquilo C1-C8, cicloalquilo C3-C8, arilo C6-C10, heterociclilo de 3-10 miembros y heteroarilo de 5-9 miembros; cada R11 y R12 se selecciona de forma independiente de hidrógeno, alquilo C1-C8, cicloalquilo C3-C8, arilo C6-C10, heterociclilo de 3-10 miembros, heteroarilo de 5-9 miembros, -CN, halógeno, -(CR16R17)tOR18, y -(CR16R17)tC(O)R18, en los que cada uno de dichos grupos alquilo C1-C8, cicloalquilo C3-C8, arilo C6-C10, heterociclilo de 3-10 miembros y heteroarilo de 5-9 miembros, está opcionalmente sustituido con uno o más grupos R15;R13 y R14 se seleccionan de forma independiente de hidrógeno, alquilo C1-C8 y cicloalquilo C3-C8, en los que dichos grupos alquilo C1-C8 y cicloalquilo están opcionalmente sustituidos con uno o más grupos R15; oR13 y R14, junto con el átomo de nitrógeno al que están unidos forman un grupo heterociclilo de 3-10 miembros, opcionalmente sustituido con uno o más grupos R15;cada R15 se selecciona de forma independiente de -(CR9R10)tR16, -(CR9R10)t(heterociclilo de 3-10 miembros), -(CR9R10)t(cicloalquilo C3-C8), -(CR9R10)t(heteroarilo de 5-9 miembros), -(CR9R10)t(arilo C6-C10), -(CR9R10)tN(R16R17), -(CR9R10)tNR16C(O)R17, -(CR9R10)tOR16, -(CR9R10)tC(O)R16, -(CR9R10)tC(O)2R16, -(CR9R10)tC(O)N(R16R17), ...
CO09010549A 2006-07-05 2009-02-04 Derivados de pirazol como inhibidores de la citocromooxidasa p450 CO6150178A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80659606P 2006-07-05 2006-07-05
US91098807P 2007-04-10 2007-04-10
US94180807P 2007-06-04 2007-06-04

Publications (1)

Publication Number Publication Date
CO6150178A2 true CO6150178A2 (es) 2010-04-20

Family

ID=38515807

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09010549A CO6150178A2 (es) 2006-07-05 2009-02-04 Derivados de pirazol como inhibidores de la citocromooxidasa p450

Country Status (24)

Country Link
US (1) US7919488B2 (es)
EP (1) EP2046774A1 (es)
KR (1) KR20090034958A (es)
CN (1) CN101511812A (es)
AP (1) AP2009004763A0 (es)
AR (1) AR062154A1 (es)
AU (1) AU2007270814B2 (es)
CA (1) CA2660031A1 (es)
CO (1) CO6150178A2 (es)
CR (1) CR10573A (es)
EA (1) EA200900135A1 (es)
GT (1) GT200700053A (es)
IL (1) IL196490A0 (es)
MA (1) MA30629B1 (es)
MX (1) MX2009000482A (es)
NO (1) NO20090346L (es)
NZ (1) NZ574207A (es)
PE (1) PE20080998A1 (es)
RS (1) RS20090036A (es)
TN (1) TN2009000033A1 (es)
TW (1) TWI334867B (es)
UY (1) UY30460A1 (es)
WO (1) WO2008004096A1 (es)
ZA (1) ZA200900478B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754107B2 (en) * 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
AU2007349176A1 (en) * 2007-03-13 2008-09-18 Arete Therapeutics, Inc. 4-piperidinylurea compounds as soluble epoxide hydrolase inhibitors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
WO2014000178A1 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
WO2014194519A1 (en) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug
WO2015070367A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
WO2015070366A1 (en) * 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
US20220144797A1 (en) * 2019-02-08 2022-05-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0024795D0 (en) 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
EP1373263B1 (en) * 2001-04-05 2004-10-27 Torrent Pharmaceuticals Ltd Heterocyclic compounds for aging-related and diabetic vascular complications
US7008953B2 (en) * 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7662844B2 (en) * 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
EA014329B1 (ru) 2005-09-23 2010-10-29 Пфайзер Продактс Инк. Пиридинаминосульфонилзамещенные бензамиды в качестве ингибиторов цитохрома р450 3а4 (cyp3a4)

Also Published As

Publication number Publication date
ZA200900478B (en) 2010-04-28
NO20090346L (no) 2009-02-19
TW200811159A (en) 2008-03-01
CN101511812A (zh) 2009-08-19
UY30460A1 (es) 2008-02-29
US20080021011A1 (en) 2008-01-24
MA30629B1 (fr) 2009-08-03
EA200900135A1 (ru) 2009-06-30
CR10573A (es) 2009-02-12
US7919488B2 (en) 2011-04-05
RS20090036A (en) 2010-06-30
NZ574207A (en) 2010-10-29
KR20090034958A (ko) 2009-04-08
PE20080998A1 (es) 2008-08-15
AR062154A1 (es) 2008-10-22
TN2009000033A1 (fr) 2010-08-19
AU2007270814A1 (en) 2008-01-10
GT200700053A (es) 2009-08-03
TWI334867B (en) 2010-12-21
MX2009000482A (es) 2009-01-27
AP2009004763A0 (en) 2009-02-28
AU2007270814B2 (en) 2011-07-14
IL196490A0 (en) 2011-07-31
EP2046774A1 (en) 2009-04-15
CA2660031A1 (en) 2008-01-10
WO2008004096A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
CO6150178A2 (es) Derivados de pirazol como inhibidores de la citocromooxidasa p450
CO6140056A2 (es) Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa
AR061667A1 (es) Arilamidas sustituidas con tetrazol
AR061486A1 (es) Derivados de 2-pirazinacarboxamida
AR063601A1 (es) Arilamidas sustituidas por tiazol u oxazol
ES2422299T3 (es) Indoles (4,5-dihidro) indoles tricíclicos
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
ES2647664T3 (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (AMD)
AR069803A1 (es) 5- anilinoimiazopiridinas y metodos de uso
RS54425B1 (en) Pyridine and Pyrazine Derivatives for Cystic Fibrosis (CF) Treatment
CO6251319A2 (es) Analogos de heteroaril amidas como antagonistas receptores p2x7
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
AR050620A1 (es) Derivados de n-2 adamantanil -2- fenoxi- acetamida como inhibidores de deshidrogenasa 11-beta hidroxiesteroide
AR062666A1 (es) Benzotriazoles como moduladores de quinasas
AR079164A1 (es) Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.
ES2570745T3 (es) Aza-heterociclos bicíclicos y su uso
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR049344A1 (es) Inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa de tipo 1
AR050529A1 (es) Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa
AR071207A1 (es) Derivados de benzofurano, benzotiazol y/o benzotiofeno moduladores de receptores farnesoides fxr, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos como para tratar dislipemias, obesidad y diabetes, entre otras enfermedades.
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
HRP20100283T8 (en) Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.